Drug Trial Radar · NCT06904222
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Guangzhou Patronus Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 1 study in China will evaluate the safety and immunogenicity of the the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in adults aged 18 years and older.
Conditions
- Respiratory Syncytial Virus Infection
Interventions
Low dose antigen of LYB005 without A01B adjuvantBiological
0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
Low dose antigen of LYB005 with A01B adjuvantBiological
0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
Middle dose antigen of LYB005 without A01B adjuvantBiological
0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
Middle dose antigen of LYB005 with A01B adjuvantBiological
0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
High dose antigen of LYB005 without A01B adjuvantBiological
0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
High dose antigen of LYB005 with A01B adjuvantBiological
0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
PlaceboBiological
0.5 mL 0.9% sodium chloride (normal saline) injection per dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of immediate adverse eventsTime frame: Within 30 minutes after vaccination
- Incidence of solicited AETime frame: Within 0-7 days after vaccination
- Incidence of unsolicited AEsTime frame: Within 28 days after vaccination
- Incidence of clinically significant abnormalities in clinical laboratory testsTime frame: 3 days after vaccination
- Occurrence of serious adverse events (SAEs) and adverse events of special interests (AESIs)Time frame: 12 months after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dangyang City Center for Disease Control and Prevention
Dangyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.